Business NewsPR NewsWire • Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma

Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma

Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma

OSLO, Norway, June 29, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® (177Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovectors-betalutin-receives-fast-track-designation-from-us-fda-fo...
Releted News by prnewswire
Lou Diamond Phillips, Brian Evans, ICE-T Celebrate Soccer in New Big Band Music Video
ASSA ABLOY Sells Certain Businesses in Relation to the Acquisition of Agta Record
D-Link 5G Solutions Revolutionize Mobile Connectivity
Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma
MedAlliance obtient le marquage CE pour SELUTION SLR™, un ballonnet coronarien à élution médicamenteuse à base de sirolimus
MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon
AGC's Light Control Glass, "WONDERLITE (TM) Dx," Makes Worldwide Debut in Toyota's New Harrier